No abstract

No abstract

Brazilian private sector was estimated to lead to an incremental annual reduction from 10,000 to 20,000 influenza-related hospitalization (where 14,000 were respiratory-related hospitalization and 6,000 were cardiovascularrelated hospitalization), from 900 to 1800 influenza-related deaths, and 11,000 influenza-related general practitioner visits, corresponding to avoided costs from USD111 million (BRL454M) to USD219 million (BRL890M), depending on the hospitalization definition. Hospitalization avoided costs represented 99% of the total avoided costs. Conclusions: Switching to TIV-HD would significantly reduce the burden of influenza especially by reducing hospitalizations that represent the most important source of cost for private market.

lifetime horizon, with costs and outcomes discounted by 3.5% per year. Univariate and multivariate probabilistic sensitivity analyses are conducted to investigate parameter uncertainty. RESULTS: The incremental cost-effectiveness ratio (ICER) for vedolizumab is estimated at £21,620/QALY compared with CT. Sensitivity analyses showed that results are most sensitive to variation in the CT arm transition probabilities from the moderately-severely active state and from the remission state. The ICER was also sensitive to response assessed at week six rather than week 8 and efficacy based on GEMINI II only. When treatment with vedolizumab was continued for 2 or 3 years (instead of 1 year) the ICER increased to £24,695/QALY and £26,207/QALY respectively. The average probabilistic ICER shows vedolizumab to be £27,428/QALY gained (95% CI ICER of -£7,883 to £82,947). CONCLUSIONS: The economic model predicts that treatment with vedolizumab improves QALYs and is a cost-effective alternative to CT for patients who have inadequate response to CT and TNF-a antagonists. Vedolizumab has received positive recommendations from the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) for the CT and anti-TNF failure population. PSY115OBJECTIVES: An increase in blood-serum-potassium levels is common in patients with renal impairment or heart failure. Lifesaving RAAS-inhibitors (RAASi) such as ACE inhibitors, AT1 receptor-antagonists and aldosterone-blockers lead to a further rise in potassium levels. Discontinuation and downtitration of RAASi result in increased morbidity, as RAASi prolong the time to complete renal insufficiency. The purpose of this study was to extend the results of an 8-week OPALeHK RCT for patiromer, a nonabsorbed potassium-binder, that showed significant reduction in hyperkalaemia and RAASi dose maintenance in the patiromer group (94%) compared to no-patiromer (placebo) arm (44%). The analysis was performed from the Austrian healthcare-systems perspective. METHODS: A reported model by Sutherland et al. (2017), composed of a decision-tree and a Markov process, was used to simulate the treatment pathway of patients with chronic-kidney-disease (CKD). The short-term decision-tree estimates the proportion of CKD patients (potassium level, 5.0mmol/L) that continued/discontinued RAASi medication after hyperkalemia. The endpoint of the decision-tree was linked with to Markov model to simulate life-time follow-up. The model includes 6 states (stable CKD, CKD disease-progression, cardiovascular (CV) events, post CV event, hospitalization and death). The cohort definition was adopted from the OPALeHK trial. Monte-Carlo simulation accounted for uncertainty. Direct costs and life expectancy were obtained from local sources for 2018. QALYs and costs were discounted at 5% p.a. RESULTS: Over lifetime, costs and outcomes associated with patiromer would amount to 38,117.17V and achieve 5.48 QALYs. Costs with no treatment are 27,157.66V and obtain 4.90 QALYs. The results show that pati...

A539index on 12 -24 and 96 -104 weeks of therapy. The costs of drug treatment from Russian healthcare system perspective were calculated for 2 years. Drug prices were derived from the list of registered maximal manufacture's prices for vital and essential drugs; expected price of secukinumab was submitted by its manufacturer. Oneway sensitivity analysis was performed. Results: Secukinumab has the lowest ICER among all biologic drugs indicated for AS treatment in Russia -€ 26,637 per patient, who has achieved ASAS20 response at 2 years. Secukinumab is also cheaper than all other biologic agents: its cost for 2 years is € 15,343, while other drugs require from € 15,926 to € 46,995 over the same period. The price of secukinumab should increase at least up to 3,6% from presently expected in order it to lose its advantages over other biologics. ConClusions: Secukinumab will provide a new cost-effective option for AS treatment in Russian Federation if the expected price is not changed.